Possible safety issue spurs pause of COVID-19 antibody study

science

science / science 279 Views comments

Possible safety issue spurs pause of COVID-19 antibody studyIndependent monitors have paused enrollment in a study testing the COVID-19 antiviral drug remdesivir plus an experimental antibody therapy being developed by Eli Lilly that’s similar to a treatment President Donald Trump recently received. Lilly confirmed Tuesday that the study had been paused “out of an abundance of caution” and said safety is its top concern. The experimental drugs are concentrated versions of one or two specific antibodies that worked best against the coronavirus in lab and animal tests.


Comments